Altimmune (ALT) Capital Expenditures (2010 - 2026)

Altimmune's (ALT) quarterly Capital Expenditures came in at $21000.0 in Q1 2026, up 2000.0% on a QoQ basis from $1000.0 in Q4 2025.

Altimmune (ALT) Capital Expenditures (2010 - 2026) Analysis & Trends

Altimmune (ALT) has 15 years of Capital Expenditures data on file, last reported at $21000.0 in Q1 2026.

On a quarterly basis, Capital Expenditures changed N/A year-over-year to $21000.0 in Q1 2026; TTM through Mar 2026 was $22000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $11000.0, changed N/A from the prior year.
Capital Expenditures for Q1 2026 stood at $21000.0, up from $1000.0 in the prior quarter.
Over the last five years, Capital Expenditures for ALT reached as high as $60000.0 in Q3 2022 and fell as low as -$4000.0 in Q2 2023.
Historically, Capital Expenditures has averaged $24375.0 across 4 years, with a median of $20000.0 in 2022.
On a YoY basis, Capital Expenditures climbed as much as 466.67% in 2023 and fell as far as 121.05% in 2023.
Year by year, Capital Expenditures stood at $38000.0 in 2022, then plunged by 110.53% to -$4000.0 in 2023, then surged by 125.0% to $1000.0 in 2025, then jumped by 2000.0% to $21000.0 in 2026.
Per Business Quant data, the three most recent Capital Expenditures figures were $21000.0 in Q1 2026, $1000.0 in Q4 2025, and -$4000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-8,939.03
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	43.25 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	786,000.00
10	Altimmune	7.96 Mn	7.96 Mn	-	21,000.00

Download Data